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It has been known for a  long time  that  the M  protein  on the surface of group A 
streptococci evokes protective immune responses against infections with the homolo- 
gous M  serotype of bacteria  (1,  2). The finding that certain antigenic determinants, 
sometimes closely associated with the M  protein, elicit antibodies that cross-react with 
host heart tissue has focused attention on defining precisely the minimal structure of 
the M  protein molecule required to evoke protective immunity (3-5). Previous studies 
(6-8)  have  shown  that  protective  immune  responses  can  be  evoked  by native  and 
synthetic peptide fragments that represent only limited regions of M  protein, indicat- 
ing that the remainder of the M  protein molecule containing potentially tissue-cross- 
reactive  antigenic  determinants  could  be  deleted  from vaccine  preparations.  It  has 
been difficult, however, to predict  the location of limited  protective regions with the 
use  of  conventional  antisera  because  these  antisera  are  polyclonal  and  contain 
antibodies to many different determinants  (8, 9), some of which may not be exposed 
in the native state of the M  protein on the bacterial surface, and others of which may 
cross-react with host tissue antigens. 
To precisely define the protective determinants of M  protein exposed on the surface 
of virulent  streptococci,  we  have  used  hybridoma  technology  to  produce  a  set  of 
monoclonal antibodies against a purified polypeptide fragment of type 24 streptococ- 
cal M  protein. In this paper we report evidence that some of the hybridoma antibodies 
are opsonic against  the homologous type streptococci. Moreover, when  injected  into 
mice,  the strongly opsonic monoctonal antibodies  protect  the  animals  against  chal- 
lenge  infections  with  the  homologous, but  not  a  heterologous,  serotype of bacteria. 
One of the hybridoma antibodies  that  reacted  in high dilution  (1:204,800)  with  the 
isolated  M  protein  failed  to  opsonize  the  organisms  or  to  protect  mice  against 
challenge infections.  We present  evidence to suggest that  the antigenic  determinant 
* Supported by research funds from the U. S. Veterans Administration, and by grants AI-10085  and AI- 
13550 from the National Institutes of Health. 
Recipient of Young Investigator Award DE-05062 from the National Institutes of Health. 
§ Medical Investigator of the U. S. Veterans Administration. Address all correspondence to: Dr. E. H. 
Beachey, Veterans Administration Medical Center, 1030  Jefferson Avenue, Memphis, TN 38104. 
II Recipient of Young Investigator Award DE-05773 from the National Institutes of Health. 
¶ Recipient of Research Traineeship Award GR-AMO7317 from the National Institutes of Health. 
10 l 0  J. ExP. MED. © The Rockefeller University Press • 0022-1007/82/04/1010/09 $1.00 
Volume 155  April 1982  1010-1018 HASTY,  BEACHEY,  SIMPSON,  AND  DALE  1011 
against  which  this  antibody  is  directed  is  "buried"  and  inaccessible  for  antibody 
binding in the native state of the M  protein on the surface of the streptococci. These 
studies  indicate  that  a  set  of monoclonal  antibodies  may  be  used  to  identify  the 
protective structural determinants of the M  protein molecule exposed on the surface 
of group A  streptococci. 
Materials and  Methods 
Myeloma  Cell Lines.  Nonsecreting myeloma cell lines Sp2/O-Agl4 (Sp2 cells) and P3-X63- 
AG8.653 (653 cells) were maintained in Dulbecco's modification of Eagle's medium (DMEM) 1 
containing horse serum (10%), calf serum (5%), nonessential amino acids (1×), h-glutamine (4 
mM; Gibco Laboratories, Grand Island Biological Co., Grand Island, NY), and gentamycin 
sulfate (100/xg/ml; Schering Corp., Kennilworth, N  J). All cells were maintained in a humidified 
incubator at 37°C with a  gas phase of 5% CO2 and 95% air. Periodically, the myeloma cells 
were treated with 8-azagnanine to insure against growth of revertant cells. 
Extraction  and  Purification  of M  Protein.  M  protein from  type 24  group  A  streptococci was 
purified from limited peptic digests as described (10,  11). The purified product, designated pep 
M24, was judged to be homogeneous by sodium dodecyl sulfate-gel electrophoresis and amino 
acid analysis (10).  Pep M5 and pep M6 were purified and analyzed similarly from type 5 and 
type 6 streptococci. 
Immunization  of Mice. Pep M24 (50 fig) was dissolved in 0.1 ml 0.02 M  phosphate/0.15 NaC1, 
pH 7.4 (PBS), emulsified with an equal volume of Freund's complete adjuvant, and injected 
subcutaneously  into  female  BALB/c  mice  (15-g).  The  same  dose  emulsified  in  Freund's 
incomplete adjuvant was repeated 1 mo later. 1-3 mo later, mice were injected intraveneously 
with 50 p,g pep M24 in PBS via the tail vein, and the animals were killed 2-3 d later. 
Cell Fusion.  Spleen cells were prepared by teasing the spleen apart with forceps and pressing 
the pieces through a stainless steel wire mesh. The cells were washed three times with serum- 
free DMEM buffered with  10 mM Hepes and collected by centrifugation at 400 g for 5 min. 
Approximately 8  ×  107 spleen cells were obtained from immunized animals. Myeloma cells 
were harvested, washed with serum-free DMEM three times, and combined with spleen cells at 
a  ratio  of 5:1  (spleen/myeloma).  The  cells  were  fused  using  polyethylene  glycol  (PEG), 
according to the method of Galfre et al. (12).  Briefly, after centrifugation the supernatant was 
removed, and 1 ml warm 50% PEG (Carbowax 1500; Fisher Scientific Co., Pittsburgh, PA) was 
added with gentle stirring of the cell pellet. After 1 rain, ~20 ml of serum-free DMEM was 
added dropwise to dilute the PEG without osmotically damaging the fused cells. The cells were 
centrifuged at 400 g, diluted to 100 ml with complete growth medium, and seeded into four 24- 
well  plates  (Costar  Data  Packaging,  Cambridge,  MA).  After 24  h,  1 ml  growth  medium 
containing hypoxanthine (100 #M), aminopterin (0.3 #M), and thymidine (16 #M) (HAT) was 
added. This was repeated three times at 24-h intervals, removing 1 ml medium from each well 
before the addition. Thereafter the medium was changed at 3-4-d intervals. After -2 wk in 
HAT, the aminopterin was removed, and after another week the hypoxanthine and thymidine 
were also removed. 
Detection of Antibody-secreting Hybridomas.  Antibody-secreting  hybridomas were detected using 
an enzyme-linked immunosorbent assay (ELISA; 13) of the culture medium supernatants. The 
assay was performed as previously described (14) using pep M24, pep M5, and pep M6 (5/xg/ 
ml) adsorbed to polystyrene tubes as the solid-phase antigen. 
In addition, to determine which antibodies were able to recognize immunodeterminants in 
their native state on the surface of Streptococcus pyogenes,  ELISA were performed using whole 
streptococci as particle phase  antigens.  In  a  series of test  tubes,  a  suspension  of log-phase 
streptococci (0.1 ml) adjusted to an absorbency of 0.2 at a wavelength of 530  nm was mixed 
with 0.1  ml of serially diluted ascites fluid and incubated for  15 min at 37°C and  15 rain at 
0°C. The cells were washed three times with PBS supplemented with 0.05%  Tween 20  (PBS- 
1 Abbreviations used in this paper." CFU, colony-forming unit;  DMEM,  Dulbecco's modification of Eagle's 
medium; ELISA, enzyme-llnked immunosorbent assay; HAT, hypoxanthine, aminopterin,  and thymidine; 
PBS, 0.02 M phosphate, 0.15 M NaCI, pH 7,2; PEG, polyethylene glycol; pep M5, M6, and M24, purified 
type 5 M, 6 M, and 24 M proteins extracted from streptococci with pepsin; PMN, neutrophilic leukocyte. 1012  MONOCLONAL  ANTIBODIES AGAINST STREPTOCOCCAL  M  PROTEIN 
Tween), resuspended in 0.2 ml of a  1:2,000 dilution of peroxidase-conjugated goat anti-mouse 
IgG (N. L. Cappel Laboratories Inc., Cochranville, PA), incubated for 30 min at 37°C, washed 
as before, and resuspended in 0.2 ml PBS-Tween. 0.15 ml of the suspension was then added to 
0.3 ml of substrate (5 amino-salicylic  acid) in a cuvette, incubated at ambient temperature for 
30 min, and the endpoint determined by measuring the absorbency at 450 nm in an automatic 
spectrophotometer (EIA PR50 Gilford Instrument Laboratories Inc., Oberlin, OH). 
Cloning Procedures. Cells from antibody-producing  wells were cloned in medium containing 
0.8% methylcellulose (Methocel A4M Premium, Dow Chemical Co. Indianapolis, IN). Similar 
procedures have been used previously for cloning of drug-resistant cell lines (15). The methyl- 
cellulose was suspended in hot water at a concentration of 4% and autoclaved. The suspension 
was dissolved by stirring overnight at 4°C and then diluted to 2% with 2× DMEM. The cells 
from positive wells were diluted to ~50 cells/ml in medium containing 0.8% methylcellulose 
and other supplements of the standard growth medium. Approximately 4 ×  10  s normal spleen 
cells were included to act as a  "feeder layer". Cloning efficiencies  using this technique were 
~50%. Within 1 wk, colonies were of a size appropriate for harvesting (~ 100 cells).  Isolated 
colonies were picked at random and seeded into 24-well plates containing  2 ml growth medium 
with or without 4 ×  105 normal spleenocytes.  Culture medium was assayed within 1 wk. Cells 
were grown to mass cultures for production of ascites fluid, re-cloned, or resuspended in growth 
medium containing an extra  20%  serum  and  10%  dimethylsulfoxide and  frozen  in liquid 
nitrogen. All antibody-producing  hybridoma clones described in this report have been re-cloned 
at least once. In all re-clones the percentages of antibody-producing  clones have generally been 
>90%. 
Ascitts Fluid. To produce large quantities of antibody, 5 ×  10  6 antibody-producing  cells were 
injected into the peritoneal cavities of BALB/c mice injected 1 wk-2 mo previously with 0.3 ml 
2,6,10,14-tetramethylpentadecane (Pristane, Aldrich Chemical Co. Inc., Milwaukee, WI). 1-2 
wk later ascites  fluid was removed, clarified by centrifugation and sterilized by membrane 
filtration. In some cases the hybridoma cells in the pellet were transferred to the peritoneal 
cavities of new mice. The IgG isotype of each hybridoma antibody was determined by double 
immunodiffusion  in agar gel of 1:200 dilutions of each ascites fluid against mouse IgG subclass 
specific antisera to IgG1, IgG2a, IgG2b, and IgG3 (Miles Laboratories Inc., Elkhart, IN). 
Preparation of Metaphase Chromosomes. Chromosome spreads of myeloma and hybridoma cells 
were performed using standard procedures (16). Cells were suspended in 0.075 M  KCI for 11- 
12 min, centrifuged, and fixed in glacial acetic acid/methanol (1:3, vol/vol) for 20 min. Drops 
of the cell suspension were placed onto a cold, wet slide, dried, and stained with Giemsa at pH 
6.8. 
Tests for  Type-specific Antibodies. Opsonization by the hybridoma antibodies was  tested by 
timed, in vitro phagocytosis tests as previously described (10, 11). The test  mixtures consisted 
of 0.4 ml of fresh, heparinized (10 U/ml) human blood, 0.5 ml of a standard suspension of type 
24, type 6, or type 5 streptococci,  and 0.05 ml of control or hybridoma ascites fluids. The ratio 
of streptococcal  units per  leukocyte was  -10:1.  The percentage of neutrophilic leukocytes 
(PMN) that had ingested one or more bacteria was estimated by microscopic examination of 
stained smears prepared from an aliquot of the test mixtures taken after 30 min of rotation at 
37°C. 
Indirect  bactericidal  tests  were  performed  as  described  (17) to  confirm  results  of  the 
opsonization assay.  0.4 ml of heparinized (10 U/ml) human blood was mixed with 0.05  ml 
control or hybridoma ascites  fluid and 0.05 ml of a suspension of streptococci containing the 
number of colony-forming  units (CFU) indicated. The mixtures were rotated for 3 h at 37°C, 
after which pour-plates were prepared by adding the test mixtures to 20 ml of 5% sheep blood 
agar. 
Mouse-protection tests  were  performed  as  described  (6). White  Swiss  mice  (15-g) were 
injected intraperitoneally  with 0.1 ml of control or hybridoma ascites fluid and challenged 24 
h later by the same route with various doses (ranging from 50 to 3 ×  105 CFU) of type 24 or 
type 6 streptococci.  Survival was recorded over a 7-d period. 
Tests for Heart  Cross-Reactive Antibodies. Frozen sections (4-#m  thick)  of human heart tissue 
were reacted at ambient temperature for 30 min with serial dilutions of each of the hybridoma 
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treated  for 30  rain  with  a  1:40 dilution  of fluorescein  labeled  goat  anti-mouse IgG, again 
washed three times in PBS, and mounted with a drop of 1% Gelvatol, pH 7.0, and a coverslip. 
The  sections  were  then  examined  using  a  Leitz  fluorescence  microscope  (E.  Leitz,  Inc., 
Roekleigh,  N  J). 
Results 
Cell Fusions.  BALB/c mice were hyperimmunized with a purified peptic extract of 
pep M24, and cells obtained from their spleens within 3 d of a final intravenous boost 
were fused with either Sp2 or 653 myeloma cells. The parental 653 cells were shown 
by analysis  of metaphase chromosomes to contain  -57  chromosomes, whereas  the 
number of chromosomes of antibody-secreting hybridomas ranged from 80 to 88. Sp2 
cells and hybrids were not analyzed for chromosome numbers. 
Culture supernatants were screened by ELISA using pep M24, pep M5, and pep 
M6  as  antigens.  Within  10  d  after the  fusions,  type-specific antibody  against  the 
immunizing  antigen  was  detected.  Cells  from  antibody-producing  colonies  were 
cloned in 0.8% methylcellulose medium, expanded by culture  in vitro, and injected 
into  the peritoneal  cavities of Pristane-primed  BALB/c mice.  5  to  10  ml of ascites 
fluid accumulated over a period of 1-3 wk. The ascites fluids produced by six different 
hybridomas were selected for the following studies. 
IgG Class, Immunoprecipitating Activity,  and ELISA  Titers of Hybridoma Antibodies.  All 
of the hybridoma antibodies were of the IgG1 isotype except clone IIA6.6, which was 
IgG2b.  ELISA titers  against  pep  M24  ranged  from  102,400  to  819,200  (Table  I); 
antibodies against pep M5 or pep M6 were not detected.  Four of the six hybridoma 
antibodies precipitated pep M24 in double diffusion tests in agar gel (Table I). None 
of the cloned antibodies precipitated heterologous types 5 or 6 pep M  proteins. These 
results suggest  that  the four precipitating antibodies  are directed  against  repeating 
antigenic  determinants,  whereas  the  two  nonprecipitating  antibodies  are  directed 
against nonrepeating determinants of the pep M24 molecule. None of the monoclonal 
antibodies reacted in immunofluorescence tests with human heart tissue. 
TABLE  I 
Type-specific Opsonic Activities of Monoclonal Antibodies* against Pep M24 
Ascites fluids used  Immunopre- 
Anti-pep M24  cipitation 
to opsonize  ELISA titers~:  with pep 
streptococci  M24 
Percentage of PMN with 
associated streptococci 
Type 24  Type 5  Type 6 
Controls§  <200  --  6  6  6 
IC 1.3]1  102,400  Yes  26  6  2 
IIC3.7[1  819,200  Yes  78  10  2 
IIC4.61[  409,600  No  86  8  2 
IIA6.8¶  102,400  Yes  58  8  6 
IIA6.6¶  204,800  No  26  8  2 
IIB4.1 ¶  204,800  Yes  4  6  2 
* All monoclonal antibodies reported are of the IgG1  isotype except IIA6.6, which is 
IgG2b. 
:[: Titers of all ascites fluids against pep M5 and pep M6 were <200. 
§ Control aseites fluid was produced by injecting 5  ×  106 Sp2 or 653 cells into the 
peritoneal cavity of mice injected 2-4 wk previously with 0.3 ml Pristane. 
[[ Produced using the 653 myeloma line. 
¶ Produced using the SP2 myeloma line. 1014  MONOCLONAL  ANTIBODIES AGAINST STREPTOCOCCAL M  PROTEIN 
Type-specific Opsonic and Bactericidal Activities of Hybridoma Antibodies.  To determine 
whether hybridoma antibodies would  effectively opsonize homologous M-type bac- 
teria, types 24, 6, or 5 streptococci were incubated in fresh heparinized human blood 
in the presence of the hybridoma ascites fluids. Five of the six ascites fluids opsonized 
type 24 streptococci to various degrees, whereas none opsonized types 5 or 6 organisms 
(Table I). The opsonic effects were confirmed by indirect bactericidal tests (Table II). 
Those  hybridoma  fluids  showing  the  strongest  opsonization  (IIC3.7,  IIC4.6,  and 
IIA6.8)  were  also  the strongest  in  the  bactericidal  tests,  completely eradicating  all 
viable streptococci in the test mixtures. The antibodies showing intermediate opsonic 
effects  gave  intermediate  values  in  the  bactericidal  test,  whereas  the  nonopsonic 
antibodies totally lacked bactericidal activity. It should be noted that no relationship 
could  be  seen  between  the  ELISA  titers  and  the  bactericidal  capacities  of  the 
hybridoma antibodies.  These results suggested that  monoclonal antibodies  directed 
against  only certain antigenic  determinants of the isolated M  protein  molecule are 
opsonic and protective. 
Protection by Hybridoma Antibodies of Mice Against Challenge S. pyogenes Infection.  Passive 
mouse protection tests were performed to determine the in vivo bactericidal activity 
of two hybridoma antibodies that were bactericidal in vitro (clones IIC3.7 and IIC4.6) 
and one that was not  bactericidal in vitro (IIB4.1). Mice were injected  intraperito- 
neally either with control ascites fluid or with ascites fluid produced  by one of the 
hybridoma  clones  and  24  h  later  were  challenged  with  either  type  24  or  type  6 
streptococci. The two strongly opsonic hybridoma antibodies were clearly protective 
(Table III). The nonopsonic antibody (IIB4.1) lacked significant protective activity. 
Thus,  although  the  latter clone  produced  antibodies  that  reacted  in  high  dilution 
(1:204,000)  with  the  isolated  pep  M24  in  ELISA,  it  did  not  produce  antibodies 
capable of opsonizing or protecting against the intact streptococci. 
Reaction of Monoclonal Antibodies with Native M  Protein on  the Surface of Intact Strepto- 
cocci.  Since clone IIB4.1 produced antibodies that reacted in high dilution with the 
isolated pep M  protein molecule, and yet failed to opsonize streptococci or to protect 
mice  against  challenge  infections,  we  investigated  the  accessibility  on  the  intact 
surface of the parent  streptococci of the antigenic  determinant  against which  these 
antibodies  were  directed.  In  these  experiments,  whole  log-phase  streptococci  were 
utilized as the solid phase M  protein antigen in ELISA. As can be seen in Table IV, 
each of the monoclonal antibodies except IIB4.1 reacted at a high dilution against the 
TABLE  II 
Indirect Bactericidal Tests of Hybridoma Ascites Fluids against Type 24 S. pyogenes 
Ascites fluid 
Number of colonies of type 24 streptococci 
after 3-h growth in test mixtures 
Inoculum51  Inoculum 14 
Control  >2,000  1,016 
ICI.3  77  62 
IIC3.7  0  0 
IIC4.6  0  0 
IIA6.8  0  0 
IIA6.6  420  159 
IIB4.1  >2,000  >2,000 HASTY, BEACHEY, SIMPSON,  AND DALE 
TABLE  III 
Type-specific Protection by Hybridoma Antibodies IIC3.7 and IIC4.6 of Mice 
Challenged with  Type 24 or Type 6 Streptococci 
1015 
Ascites fluid used to passively 
immunize mice 
LDso in mice challenged with: 
Type 24  Type 6 
streptococci  streptococci 
Control, nonimmune  <50  (0/15)*  <130 (0/15) 
Clone IIC3.7  300,000  (12/15)  <130 (1/15) 
Clone IIC4.6  300,000  (12/15)  130 (2/15) 
Clone IIB4.1  600  (5/15)  ND:~ 
* The numbers of survivors per number of mice challenged in each group are shown 
in parentheses. 
:~ Not done. 
TABLE IV 
ELISA  Titers of Hybridoma Antibodies against Intact Type 24 Streptococci 
Ascites fluid  ELISA titers against type 24 
streptococci 
Control ascites  <200 
IIC4.6  409,600 
IIC3.7  819,200 
IIA6.8  12,800 
IC1.3  51,200 
IIA6.6  51,200 
IIB4.1  <200 
whole streptococci. Thus, although the ascites fluid produced by clone IIB4.1  reacted 
at a dilution of 1:204,000 against the isolated pep M24 (see Table I), this fluid failed 
to react with the intact type 24 streptococci at a dilution as low as  1:200, indicating 
that  the antigenic  determinant  is not available  for antibody binding in  the native 
state of the M  protein. These results, therefore, are consistent with the findings that 
the  antibody  produced  by  clone  IIB4.1  is  devoid  of opsonic  or  mouse  protective 
activity. 
Discussion 
Hybridoma  technology  (18)  provides  the  cell  biologist  with  methodology  that 
renders  practical  the production of highly specific  probes  for analysis  of structure- 
function relationships of complex  macromolecules.  The  data  presented  here clearly 
demonstrate  the type-specific  opsonic and protective properties  of several  distinctly 
different hybridoma antibodies raised against a structurally defined fragment of type 
24  streptococcal  M  protein,  a  complex  bacterial  cell  surface  macromolecule  that 
renders these microorganisms resistant to phagocytosis in the nonimmune host. 
Because hybridoma antibodies are directed against a single distinct immunodeter- 
minant,  it  is  assumed  that  the  antibodies  that  precipitated  pep  M24  in  double 
immunodiffusion  tests are directed  against an immunodeterminant  that is repeated 
at  least  once  in  the  molecule  to  enable  lattice  formation  between  antigen  and 
antibody.  The  concept  of repeating  antigenic  determinants  is  consistent  with  the 
repeating covalent structure of streptococcal M  protein established in our laboratories 1016  MONOCLONAL ANTIBODIES AGAINST STREPTOCOCCAL M PROTEIN 
(7,  10) as well as by Manjula and Fischetti (19,  20).  Our studies do not exclude the 
possibility, however, that the nonprecipitating hybridoma antibodies may be directed 
against a determinant repeated in another fragment of M  protein that may not have 
been included in the fragment extracted with pepsin during the purification process; 
recent studies  (21,  22)  suggest that the native M  protein is considerably larger than 
the pep M  protein fragment. 
Neither  the  ability  to  precipitate  pep  M24  nor  the  ELISA  titer  of hybridoma 
antibodies correlated with opsonic, bactericidal, or protective activity. In fact, one of 
the  nonprecipitating  antibodies,  IIC4.6,  was  equal  in  opsonic,  bactericidal,  and 
protective activity to the strongest opsonin among the precipitating antibodies, IIC3.7. 
One precipitating hybridoma antibody (IIB4.1), which had a high ELISA titer against 
pep M24, was neither opsonic nor protective. 
Several alternative explanations could have accounted for the lack of protective 
activity of antibodies produced by clone IIB4.1. First, the antibody may have been 
directed toward a  determinant not involved in the antiphagocytic activity of the M 
protein.  Second,  the  antibody  may  have  been  able  to  bind  to  the  M  protein 
determinant, but because of an internal location on the streptococcal surface may not 
have been recognized by complement or phagocytic cells.  This latter situation has 
been suggested to be responsible for the antiphagocytic effect of the capsules of certain 
strains of Staphylococcus aureus (23). Third, a new antigenic determinant may have been 
created on the isolated M  protein fragment during the pepsin extraction procedure. 
Finally, the antigenic determinant may have been buried in the surface M  protein in 
its native conformation either by other surface structures or within molecular folds on 
the  M  protein  molecule itself.  The  last  hypothesis  is  consistent  with  our previous 
observation that certain immunodeterminants exposed on the surface of one serotype 
of M protein may be buried in the molecular-folds of another (14). Our data, obtained 
by using intact streptococci as the solid phase antigen  in  ELISA, support  the idea 
that  the  antigenic  determinants  against  which  the  antibodies  in  clone IIB4.1  are 
directed are inaccessible in the native state of M  protein on the intact streptococcal 
surface. Recent studies  (E.  H. Beachey et al., manuscript  in preparation) show that 
this antibody binds to peptide fragments of pep M24, indicating that the antibody is 
directed against antigenic determinants of the M  protein molecule and not against a 
contaminating antigen. 
Thus, not all of the immunodeterminants of type 24 M  protein are exposed on the 
surface of the  intact  bacteria.  This may explain  the  disparity reported by several 
investigators between the opsonizing and  immunoprecipitating activities of certain 
antisera directed against streptococcal M protein (24-27). If the immunoprecipitating 
antisera contained a predominance of antibodies directed only at determinants buried 
on the surface of intact organisms, one would expect an inability of the antisera to 
opsonize the  organisms.  On  the other hand,  those sera  having a  predominance of 
antibodies  directed  against  a  nonrepeating  antigenic  determinant  exposed  on  the 
surface of the bacteria would  be opsonic, but  would  fail to precipitate isolated M 
protein. 
We have presented data in previous studies  (7, 8)  demonstrating that  the whole 
pep  M24  molecule  is  not  needed  for  the  development  of protective  immunity. 
Evidence presented here suggests the possibility that a  single antigenic determinant 
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Further  studies  to  determine  precise  antibody-combining  sites  will  be  useful  in 
determining the minimum peptide sequence necessary to evoke protective immunity 
against homologous streptococci. Small protective determinants from several different 
serotypes of M  protein could then be included in a multivalent vaccine which would 
be free of nonessential  strt, ctures  that  may give rise to toxic or tissue cross-reactive 
responses. 
Summary 
Hybridoma technology was used to produce a set of monoclonal antibodies against 
a  purified polypeptide fragment of type 24 streptococcal M  protein to delineate the 
protective determinants of M  protein exposed on the surface of the virulent strepto- 
cocci. Several hybridoma antibodies were found to be opsonic against the homologous 
type streptococci. At least two of these antibodies (IIC3.7 and IIC4.6) protected mice 
against challenge infections with the homologous, but not a heterologous, serotype of 
bacteria. One of the hybridoma antibodies that reacted in high dilution  (1:204,800) 
with the isolated M  protein failed to react with the M  protein on the surface of type 
24 streptococci, and thus did not opsonize the homologous organisms or protect mice 
against  challenge  infections.  Because  hybridoma  antibodies  are  directed  against  a 
single distinct  immunodeterminant,  these results indicate  that protective immunity 
may be directed at any one of several distinct  antigenic determinants of M  protein 
exposed on the surface of virulent group A streptococci. 
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